Tranexamic acid may help control GI bleeding, prevent rebleeding in cirrhosis patients: Study
Tranexamic acid may help control GI bleeding, and prevent rebleeding in cirrhosis patients suggests a study published in the Hepatology.
Patients with Child-Turcotte-Pugh class B and C cirrhosis with upper gastrointestinal bleeding (UGIB) have systemic as well as localized (in the mucosa of the esophagus and stomach) fibrinolysis. The aim of this study was to evaluate the efficacy and safety of tranexamic acid in the treatment of acute UGIB in patients with cirrhosis. A total of 600 patients with advanced liver cirrhosis (Child-Turcotte-Pugh class B or C) presenting with UGIB were randomly allocated to either the tranexamic acid (n=300) or the placebo group (n=300). The primary outcome measure was the proportion of patients developing 5-day treatment failure. Failure to control bleeding by day 5 was seen in 19/300 (6.3%) patients in the tranexamic acid group and 40/300 (13.3%) patients in the placebo group (p=0.006). Esophageal endoscopic variceal ligation (EVL) site as a source of failure to control bleeding by day 5 among patients undergoing first-time esophageal EVL (excluding patients with a previous post-EVL ulcer as a source of bleed) was seen in 11/222 (4.9%) patients in the tranexamic acid group and 27/225 (1212.0%) patients in the placebo group (p=0.005). However, 5-day and 6-week mortality was similar in the tranexamic acid and placebo groups.
Tranexamic acid significantly reduces the failure to control bleeding by day 5 and failure to prevent rebleeding after day 5 to 6 weeks in patients with advanced liver cirrhosis (Child-Turcotte-Pugh class B or C) presenting with UGIB, by preventing bleeding from the EVL site.
Reference:
Kumar, Manoj1; Venishetty, Shantan1; Jindal, Ankur1; Bihari, Chhagan2; Maiwall, Rakhi1; Vijayaraghavan, Rajan1; Saggere Muralikrishna, Shasthry1; Arora, Vinod1; Kumar, Guresh3; Sarin, Shiv K.1. Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis: A randomized controlled trial. Hepatology 80(2):p 376-388, August 2024. | DOI: 10.1097/HEP.0000000000000817
Keywords:
Tranexamic, acid, control, GI bleeding, prevent, rebleeding, cirrhosis patients, study, Kumar, Manoj1; Venishetty, Shantan1; Jindal, Ankur1; Bihari, Chhagan2; Maiwall, Rakhi1; Vijayaraghavan, Rajan1; Saggere Muralikrishna, Shasthry1; Arora, Vinod1; Kumar, Guresh3; Sarin, Shiv K
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.